---
document_datetime: 2024-11-27 14:07:44
document_pages: 59
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/copalia-hct-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: copalia-hct-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 128.6970763
conversion_datetime: 2025-12-15 22:41:44.736286
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Copalia HCT

Proceduralstepstakenandscientificinformationaftertheauthorisation

| Application number   | Scope                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued2 / amended on   | Product Information affected3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IG/1804              | B.II.b.2.c.1 - Change to importer, batch release arrangements andquality controltestingof theFP- Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Not includingbatch control/testing | 21/11/2024                          |                                            | Annex II and PL                 |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex I, Labelling, PL (Package Leaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annexII, labelling,package leaflet).The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a)of Regulation(Eu)No.712/2012, or within one year for other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| WS/2656/G   | Thiswas an applicationfor agroupofvariations followingaworksharingprocedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.III.1.a.3-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Newcertificatefrom a newmanufacturer(replacementor addition)   | 05/09/2024   | n/a   |             |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|
| IG/1784     | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                         | 28/08/2024   | n/a   |             |
| IG/1780     | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/08/2024   | n/a   |             |
| IG/1708     | B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                  | 08/04/2024   | n/a   |             |
| WS/2609     | Thiswasanapplicationfor avariationfollowinga worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                        | 25/01/2024   |       | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|           | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                     |            |            |          |                               |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------|
| IG/1666/G | This was an application for a group of variations. A.4-Administrativechange-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureof theASor manufacturerofanovelexcipient A.4-Administrative change-Change in thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureof theASor | 14/09/2023 | n/a        |          | manufacturerofanovelexcipient |
| WS/2513   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.z -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation，includingtheRMP-Othervariation                                                                                                                                                                    | 14/09/2023 | 03/11/2023 | Annex II |                               |
| IG/1645/G | This was an applicationfor a group of variations. A.7-Administrative change-Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7-Administrativechange-Deletionof                                                                                                                                                                                                                                 | 08/08/2023 | n/a        |          | manufacturing sites           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IG/1637   | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19/07/2023   | n/a   |                                                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------------------|
| WS/2411/G | This was an applicationfor a group ofvariations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.II.b.4.a -Change in the batch size (including batch sizeranges)of thefinishedproduct-Upto10-fold compared to the originally approved batch size B.II.b.4.a -Change in the batch size (including batch size ranges) of the finished product -Up to 10-fold compared to the originally approved batch size B.II.b.3.a-Change in the manufacturingprocess of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.z-Change in the manufacturing process of thefinished orintermediateproduct-Othervariation B.II.b.3.z-Changeinthemanufacturingprocessof thefinishedorintermediateproduct-Othervariation B.II.b.4.a-Change in thebatch size(includingbatch sizeranges)of thefinishedproduct-Upto10-fold compared to the originally approved batch size B.II.b.3.a-Change in the manufacturing process of thefinishedorintermediateproduct-Minorchange inthemanufacturingprocess B.II.b.3.z - Change in the manufacturing process of | 30/03/2023   | n/a   | thefinishedorintermediateproduct-Othervariation |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.4.a - Change in the batch size (including batch sizeranges)of the finishedproduct-Up to10-fold comparedtotheoriginallyapprovedbatchsize B.I1.b.4.a-Changeinthebatchsize(includingbatch size ranges) of the finished product - Up to 10-fold compared to the originally approvedbatch size B.II.b.3.a-Change in themanufacturingprocessof the finished or intermediate product - Minor change inthemanufacturingprocess   |            |            |                   |                                                                                                                             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------|
| IG/1604/G | Thiswasanapplicationforagroupofvariations. A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletion of                                                                                                                                                                  | 21/03/2023 | n/a        |                   |                                                                                                                             |
| WS/2373   | This was an application for a variation following a worksharingprocedureaccording toArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.a-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of wordingagreedbythecompetentauthority                                                                                                             | 15/12/2022 | 03/11/2023 | SmPC and Annex II | ToupdateAnnexII torequest anextensionof thedue date forthefulfilmentofconditionB,from'26September2022' to'01 0ctober 2023'. |
| WS/2338   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of                                                                                                                                                                                                                                                                                                                                  | 10/11/2022 | 03/11/2023 | SmPC              | Toupdatesection4.9of theSmPC,toimplementthe wording related to the risk of non-cardiogenic pulmonary                        |

<div style=\"page-break-after: always\"></div>

|           | CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                            |            |     | oedemainamlodipineoverdose.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------|
| WS/2278/G | This was an application for a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. B.IIl.1.a.3-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-New certificate from a newmanufacturer(replacement or addition) B.I.a.1.f-Change in themanufacturer of ASor of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 27/10/2022 | n/a |                               |
| IG/1523   | A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/06/2022 | n/a |                               |
| WS/2256/G | Thiswasanapplicationforagroupofvariations following aworksharingprocedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                     | 02/06/2022 | n/a |                               |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.c-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionof anew specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontrol testing arrangementsfor theAS-replacement oradditionofasitewhere   |            |            |             |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| WS/2237 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 31/03/2022 | 02/09/2022 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                     | VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                            |                                                                                                                                                                         |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10344 /202106 | Periodic Safety Update EU Single assessment - amlodipine / valsartan, amlodipine / hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 10/02/2022 | n/a        |                            | PRACRecommendation-maintenance                                                                                                                                          |
| WS/2207             | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. TobringtheannexesinlinewiththecurrentQRD templatev10.2.InadditiontheMAH hastaken the opportunity to update the local contact details for the UK (Northern Ireland). C.I.z - Changes (Safety/Efficacy) of Human and                                                                                                                                                                                                                               | 03/02/2022 | 02/09/2022 | Annex II, Labelling and PL | Tobring the annexes inlinewith the current QRDtemplate v10.2. In addition the MAH has taken the opportunity to updatethelocal contactdetailsfortheUK(Northern Ireland). |
| IG/1440/G           | Thiswas an applicationfor a group of variations. B.IIl.1.a.2-Submission of a new/updated or deletionofPh.Eur.Certificate ofSuitabilityto the relevant Ph.Eur.Monograph-Updated certificate fromanalreadyapprovedmanufacturer A.4-Administrative change-Change in the name and/oraddressof amanufactureror anASMFholder orsupplierof theAS，startingmaterial,reagentor intermediateusedinthemanufactureof theASor manufacturer of a novel excipient A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor | 29/11/2021 | n/a        |                            |                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | intermediateused in themanufacture of theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                 |         |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------|
|           | Thiswas an applicationfor avariationfollowing a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. C.1.11.z -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 02/09/2021 | 02/09/2022 | Annex II        | WS/2109 |
| WS/2090/G | Thiswas an applicationfor agroupofvariations followingaworksharingprocedure accordingto Article20of CommissionRegulation(EC)No 1234/2008. B.1I.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsibleforimportation and/orbatchrelease- Notincludingbatchcontrol/testing A.5.b-Administrative change -Change in the name and/or addressofamanufacturer/importerofthe finishedproduct,including quality control sites (excludingmanufacturerforbatchrelease) B.II.e.4.a-Change in shape ordimensions of the container or closure (immediate packaging) - Non- sterile medicinal products B.II.b.3.z - Change in the manufacturing process of thefinished orintermediateproduct-Other variation B.II.b.2.c.2-Change to importer,batch release | 02/09/2021 | 02/09/2022 | Annex II and PL |         |

<div style=\"page-break-after: always\"></div>

|         | Including batch control/testing B.II.b.1.e-Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release,batchcontrol,primaryandsecondary packaging,fornon-sterilemedicinalproducts                                                                                                                |            |            |          |                                                |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------|
|         | Thiswas an applicationfor a group of variations. C.1.11.a -Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,includingtheRMp-Implementationof wording agreed by the competent authority C.1.11.a-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of | 26/04/2021 | 17/06/2021 | Annex II | IG/1383/G wordingagreedbythecompetentauthority |
| WS/2019 | This was an application for a variation following a worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. B.I.b.1.h -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa specification parameter as a result of a safety or        | 15/04/2021 | n/a        |          | quality issue                                  |
|         | Thiswas anapplicationfor agroupofvariations following a worksharing procedure according to Article20of CommissionRegulation(EC)No                                                                                                                                                                                                                                             | 15/04/2021 | n/a        |          | WS/2022/G                                      |

<div style=\"page-break-after: always\"></div>

|          | 1234/2008. B.I.b.1.c-Change in the specification parameters and/or limits of anAS,starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approvedmanufacturer                                                           |            |            |          |                                                                            |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|----------------------------------------------------------------------------|
| A31/0069 | The European Commission triggered a referral under Article31ofDirective2001/83/ECandrequestedthe CHMP to assess the impact of nitrosamine impurities on the benefit-risk balance of valsartan-containing medicinalproductsandtoissue arecommendation onwhethertherelevantmarketingauthorisations shouldbe maintained,varied,suspended orrevoked. During theCHMPplenarymeetinginSeptember 2018, the scope of the referral has been widened to includeallsartanswithatetrazolegroupintheir molecular structure (candesartan, irbesartan, losartan, olmesartan and valsartan).The CHMP Opinion was issued on 31 January 2019 and the CommissionDecisionwasissuedon11April2019. | 12/11/2020 | 19/02/2021 | Annex II | Pleasereferto the assessmentreport: CopaliaHCTEMEA/H/A-31/1471/C/1159/0069 |

<div style=\"page-break-after: always\"></div>

|         | CommissionrequestedtheEMA toassess theimpact of theoutcome of theArticle5(3)assessment on nitrosaminesadoptedon25June2020on the CHMP'sopinionof31January2019forthescientific assessmentandreviewunderArticle31ofDirective 2001/83/ECregardingangiotensin-II-receptor antagonists (sartans) containing a tetrazole group (EMEA/H/A-31/1471).The CHMPwasrequested to give its recommendation whether the conditions of the Marketing Authorisations should bevaried.   |            |            |          |           |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------|
| IG/1325 | A.4-Administrative change-Change in the name and/or address of a manufacturer or an ASMF holder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufacture of theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                             | 06/01/2021 | n/a        |          |           |
| IG/1318 | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                       | 07/12/2020 | n/a        |          |           |
|         | Thiswas an applicationfor a group of variations. A.4-Administrative change-Change in the name and/oraddressof amanufactureror anASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient B.I.a.1.f-Change in the manufacturer of AS or of a                                                                                                                                                   | 20/10/2020 | 17/06/2021 | Annex II | IB/0087/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.b.1.h-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.z-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other variation B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | relevant Ph. Eur. Monograph - Updated certificate from an already approvedmanufacturer B.II1.1.a.3-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevant Ph. Eur. Monograph - New certificate from a newmanufacturer(replacementor addition)                                                                                                                                                                                |            |            |             |                                          |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------|
|         | C.I.z-Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                         | 23/06/2020 | 17/06/2021 | SmPC and PL | IG/1255                                  |
|         | This was an applicationfor a group ofvariations. A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS,startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturer of a novel excipient B.I.a.1.f-Change in themanufacturer ofASor of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere | 15/05/2020 | n/a        |             | IG/1254/G batchcontrol/testingtakesplace |
| IG/1207 | B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                      | 31/01/2020 | n/a        |             |                                          |
|         | Thiswas anapplicationfor a groupofvariations. B.I.a.1.f-ChangeinthemanufacturerofASorofa starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                      | 19/12/2019 | n/a        |             | IG/1179/G                                |

<div style=\"page-break-after: always\"></div>

| Changestoqualitycontroltesting arrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in the manufacturer ofASor of a starting material/reagent/intermediate for AS - Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.III.1.a.1 -Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevant Ph.Eur.Monograph-New certificate from an already approved manufacturer B.Ill.1.a.2-Submissionofanew/updatedor deletionofPh.Eur.CertificateofSuitabilitytothe relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer   |            |     |           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/oraddressof amanufacturer/importerofthe finished product, including quality control sites (excluding manufacturer for batch release) A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof manufacturingsites B.II.b.2.a-Change to importer,batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testingtakesplace                                                                                                                                                                        | 11/12/2019 | n/a | IG/1175/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| WS/1656/G   | Thiswas anapplicationfor agroupofvariations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31/10/2019   | 18/06/2020   | Annex II   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------|
|             | following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.I.a.1.f -Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testing takesplace B.I.a.1.f -Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Addition or replacement(excl.Biol.orimmunol.substance)ofa specification parameter as a result of a safety or quality issue B.I.b.1.h-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue B.I.b.2.a-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.2.z - Change in test procedure for AS or |              |              |            |

<div style=\"page-break-after: always\"></div>

|           | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                  |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------|
| IG/1148   | B.IIl.1.a.4-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-Deletion of certificates (in case multiplecertificatesexistper material)                                                                                                                                                                                                                                                                 | 04/10/2019 | n/a        |                                  |           |
|           | Thiswas an applicationfor a group of variations. B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.III.1.a.3-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilityto the relevant Ph. Eur. Monograph - New certificate from a newmanufacturer(replacementoraddition) | 08/08/2019 | n/a        |                                  | IG/1111/G |
| IG/1117/G | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturing sites B.11.b.2.c.1-Change to importer,batch release arrangements and quality control testing of the FP - Replacementoradditionofamanufacturer responsible for importation and/or batch release - Notincludingbatchcontrol/testing                                                                                                                         | 05/07/2019 | 18/06/2020 | SmPC, Annex II, Labelling and PL |           |
|           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including theRMP-Implementation of                                                                                                                                                                                                                                                                                                                    | 05/07/2019 | n/a        |                                  | IG/1112   |

<div style=\"page-break-after: always\"></div>

|         | wordingagreedbythecompetentauthority                                                                                                                                                                                                                                 |            |            |                            |                                                       |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|-------------------------------------------------------|
| IG/1100 | A.7-Administrativechange-Deletionof manufacturingsites                                                                                                                                                                                                               | 24/05/2019 | n/a        |                            |                                                       |
|         | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                        | 24/05/2019 | n/a        |                            | IG/1099                                               |
| IG/1098 | B.III.1.a.2-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitabilitytothe relevantPh.Eur.Monograph-Updated certificate fromanalreadyapprovedmanufacturer                                                                                             | 29/04/2019 | n/a        |                            |                                                       |
| IG/1056 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of theAS                                                                                                                                                      | 11/02/2019 | n/a        |                            |                                                       |
| IG/1017 | C.I.z-Changes (Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                               | 11/12/2018 | 11/04/2019 | SmPC and PL                |                                                       |
| IG/0986 | C.I.z-Changes(Safety/Efficacy)ofHumanand VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                  | 17/10/2018 | 11/04/2019 | Annex II, Labelling and PL |                                                       |
|         | Thiswas an applicationfor a group of variations. B.I.a.1.f-Change in themanufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacement oradditionof asitewhere batchcontrol/testingtakesplace | 10/09/2018 | n/a        |                            | IG/0975/G B.II1.1.a.1 -Submission of a new/updated or |

<div style=\"page-break-after: always\"></div>

|        | deletion ofPh.Eur.Certificate ofSuitability to the relevant Ph. Eur. Monograph - New certificate from an already approvedmanufacturer                                                                                                                                                                                                     |            |            |                        |           |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| T/0067 | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                                          | 16/05/2018 | 25/06/2018 | SmPC, Labelling and PL |           |
|        | A.5.b - Administrative change - Change in the name and/oraddressofamanufacturer/importerofthe finished product,including quality control sites (excluding manufacturerforbatchrelease)                                                                                                                                                    | 21/06/2018 | n/a        |                        | IG/0947   |
|        | C.I.3.a - Change(s) in the SPC, Labelling or PL intendedtoimplementtheoutcomeofaprocedure concermingPSURorPASSortheoutcomeofthe assessmentdoneunderA45/46-Implementationof wording agreed by the competent authority                                                                                                                      | 17/04/2018 | 25/06/2018 | SmPC and PL            | IG/0910   |
|        | B.II.c.1.a-Change in the specificationparameters and/or limits of an excipient -Tightening of specification limits                                                                                                                                                                                                                        | 26/03/2018 | n/a        |                        | IG/0913   |
|        | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its | 15/03/2018 | n/a        |                        | WS/1291/G |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.b-Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b-Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof atestprocedurefortheASorastarting material/reagent/intermediate,if analternativetest procedure is already authorised B.I.b.2.b -Change in test procedure forAS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.b - Change in test procedure for AS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test procedure is already authorised B.I.b.2.b-Change in test procedure for AS or startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| startingmaterial/reagent/intermediate-Deletionof a test procedure for the AS or a starting material/reagent/intermediate,if an alternative test procedure is already authorised B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                       |            |     |           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| A.4-Administrative change-Change in the name and/oraddressofamanufactureroranASMFholder orsupplieroftheAS，startingmaterial,reagentor intermediateused in themanufactureof theASor manufacturerofanovelexcipient                                                                                                                                                                                                                                                 | 01/12/2017 | n/a | IG/0863   |
| B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificate ofSuitability to the relevantPh.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                | 03/08/2017 | n/a | IG/0826   |
| This was an application for a group of variations. B.II.d.1.a-Change in the specificationparameters and/or limits of thefinishedproduct-Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/orlimits of the finished product-Tightening of specification limits B.II.d.1.z - Change in the specification parameters and/orlimitsofthefinishedproduct-Othervariation B.II.d.2.a-Change in test procedure for the finished | 28/07/2017 | n/a | IG/0817/G |

<div style=\"page-break-after: always\"></div>

|                     | product-Minor changesto an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.b-Change in test procedure for the finished product-Deletionof atestprocedureif an alternativemethod is already authorised B.II.d.2.b - Change in test procedure for the finished product-Deletion of a testprocedureif an alternativemethod is already authorised   |            |            |             |                                |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------|
| IG/0805             | A.7 - Administrative change - Deletion of manufacturingsites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 23/05/2017 | n/a        |             |                                |
| PSUSA/10344 /201606 | PeriodicSafetyUpdateEUSingleassessment- amlodipine / valsartan, amlodipine / hydrochlorothiazide/valsartan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/03/2017 | n/a        |             | PRACRecommendation-maintenance |
| IG/0776             | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/02/2017 | n/a        |             |                                |
| WS/1080             | This was an application for a variation following a worksharing procedure according to Article 20 of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/02/2017 | 30/01/2018 | SmPC and PL |                                |

<div style=\"page-break-after: always\"></div>

|           | CommissionRegulation(EC)No1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |     |                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------|
| IG/0733/G | This was an application for a group of variations. A.7-Administrative change-Deletion of manufacturing sites A.7-Administrative change-Deletionof manufacturingsites A.7-Administrativechange-Deletionof                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/09/2016 | n/a | manufacturing sites |
| IG/0727/G | This was an application for a group of variations. B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f-Change in themanufacturer of ASor of a starting material/reagent/intermediate for AS - Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a -Change in test procedure for AS or starting material/reagent/intermediate-Minor changes to an approved testprocedure | 14/09/2016 | n/a |                     |

<div style=\"page-break-after: always\"></div>

| IG/0707   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                       | 21/07/2016   | n/a   |                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------|
| IG/0706   | B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                                                                                | 21/07/2016   | n/a   |                               |
| WS/0704   | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. B.1.b.1.c-Change in thespecificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its correspondingtestmethod | 17/12/2015   | n/a   |                               |
|           | This was an applicationfor a group of variations. A.5.b -Administrative change -Change in the name and/or addressofamanufacturer/importerof the finished product, including quality control sites (excluding manufacturerforbatchrelease) A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrativechange-Deletionof            | 06/07/2015   | n/a   | IG/0585/G manufacturing sites |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.a-Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0710   | Thiswasanapplicationforavariationfollowinga worksharing procedure according to Article 20 of CommissionRegulation(EC)No1234/2008. Changesrelated tothe amlodipinecomponent Updateofsection4.2of theSmPCtoincluderevised dosing recommendations in patients with hepatic impairment and in elderly patients. Changesrelatedtothevalsartancomponent Updateofsection4.8oftheSmPCtoupdatethe Preferred Term asperMedDRAversion17. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and the Package Leaflet. C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/03/2015 | 05/05/2015 | SmPC and PL | Theposologysectionisupdated tohighlightthatwhen switchingeligiblehypertensivepatientswithhepatic impairmentorelderlyhypertensivepatientsto amlodipine or Exforge, the lowest available dose of amlodipine monotherapy or of the amlodipine component, respectively, should be used. |
| IG/0539   | C.I.1.a-Change(s) in the SPC, Labelling or PL intendedtoimplementtheoutcomeofaUnion referralprocedure-Theproduct isnotcoveredby the definedscope of theprocedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 27/03/2015 | 22/03/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                     |
| IG/0532/G | This was an applicationfor a group ofvariations. B.II1.1.a.2-Submission of a new/updated or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/02/2015 | n/a        |             |                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability tothe relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.II1.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability tothe relevant Ph.Eur.Monograph-Updated certificate from an already approved manufacturer                                                                                                    |            |            |                     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|
| IG/0528/G | Thiswasanapplicationforagroupofvariations. A.4-Administrative change-Changein thename and/oraddressofamanufactureroranASMFholder orsupplieroftheAS,startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient B.1.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tightening of specification limits B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method | 17/02/2015 | n/a        |                     |
| IG/0527   | A.1-Administrative change -Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/02/2015 | 05/05/2015 | SmPC, Labelling and |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     | PL   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| WS/0616/G | Thiswasanapplicationforagroupofvariations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.d-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of anobsoleteparameter) B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure | 18/12/2014 | n/a |      |
| WS/0634/G | Thiswasanapplicationforagroupofvariations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Replacementof2testmethodsforanactive substance intermediate. Toincudeaminor changein a testmethodfor an                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 23/10/2014 | n/a |      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| active substanceintermediate. Toadd3testmethodsfor an activesubstance intermediate. To change the specification parameter for an active substance intermediate B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | corresponding test method B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |                                                                     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------|
| WS/0636/G | This was an application for a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. To implement changes in the manufacturing process of the active substance. B.I.a.2.z-Changes in the manufacturing process of theAS-Othervariation B.I.a.2.z - Changes in the manufacturing process of theAS-Othervariation B.I.a.2.a-Changes in themanufacturingprocess of theAS-Minor changein themanufacturingprocess of theAS B.I.a.2.a-Changes in themanufacturing process of theAS-Minor change in themanufacturingprocess of theAS B.I.a.4.z-Change to in-process tests orlimits applied during the manufacture of the AS - Other variation B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew | 23/10/2014 | n/a | Toimplementchangesin themanufacturingprocessof the active substance |

<div style=\"page-break-after: always\"></div>

|           | corresponding test method B.I.a.2.z-Changes in the manufacturing process of the AS-Other variation B.I.a.2.z - Changes in the manufacturing process of theAS-Othervariation B.I.a.2.a - Changes in the manufacturing process of theAS-Minor change in themanufacturingprocess of the AS B.I.a.2.a-Changes in the manufacturing process of the AS-Minor change in the manufacturingprocess of the AS                                                                                                                                                                                                                 |            |     |                                            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------|
| WS/0633/G | Thiswasanapplicationfor agroupofvariations followingaworksharingprocedure accordingto Article20of CommissionRegulation(EC)No 1234/2008. Toreplace3testmethodsfor anactivesubstance intermediate. Toincludeaminorchangetoanapprovedtest procedure for an active susbance intermediate. Toadd a testmethod or an activesubstance intermediate. Toadd2alternativetestmethodsfor anactive substanceintermediate. B.I.b.2.e -Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 23/10/2014 | n/a | B.I.b.2.a-Change in testprocedure forAS or |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.1.c-Changeinthespecificationparameters and/or limits of an AS, starting material/intermediate/reagent -Addition of a new specification parameter to the specification with its correspondingtestmethod B.I.b.2.e-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits corresponding test method B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/0635/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/10/2014 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|          | Toadd an alternativemanufacturer of AS intermediates. Toincrease thebatchsizesforASintermediatesfor the new manufacturing site Todelete amanufacturingsiteforASintermediates. B.I.a.1.z-ChangeinthemanufacturerofASorofa starting material/reagent/intermediate for AS - Other variation B.I.a.3.a -Change in batch size(including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size A.7-Administrativechange-Deletionof manufacturing sites                                                                                                                                                                              |            |            |             |                                                                                                                              |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------|
| A31/0030 | On17April2013,furthertotheemergenceofnew evidence from the scientific literature on dual RAS blockadetherapyandgiventheseriousnessofthe identified safety concerns, the Italian Medicines Agency (AIFA) initiated a review under Article 31 of Council Directive 2001/83/EC, requesting the PharmacovigilanceRiskAssessmentCommittee (PRAC)toissue arecommendation on thebenefit- riskofdualRASblockadetherapythroughthe combined use of angiotensin-converting enzyme inhibitors (ACE-inhibitors), angiotensin II receptor blockers(ARBs)oraliskiren and to determine whetheranyregulatorymeasuresshouldbetakenon themarketingauthorisations of theproducts involved in this procedure. | 22/05/2014 | 04/09/2014 | SmPC and PL | Forfurtherinformationpleaserefer to theRenin- angiotensin-system (RAS)-acting agents Article 31 referral -Assessment report. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| R/0038   | Renewal of themarketingauthorisation.                                                                                                                                                                                                                     | 25/04/2014   | 04/07/2014   | SmPC andPL   | Exforge HCT is a fixed dose combination (FDC) medicinal product containing amlodipine, a dihydropyridine derivative, valsartan, an angiotensin II antagonist and hydrochlorothiazide, a well-known thiazide diuretic. Exforge HCTisindicatedforthetreatmentofessential hypertension assubstitution therapyinadultpatientswhoseblood pressure is adequately controlled on the combination of amlodipine,valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual- component and a single-componentformulation. Theefficacydatacollectedsincetheinitial MAAonthe combination of amlodipine/valsartan/HCTZremain in accordance with the previous cumulative experience and the efficacy information presented in the Summary of Product Characteristics(SmPC).The safety data remain in accordance with the previous cumulative experience describedinthePSURsand thesafetyinformation presented in the Core Data Sheet (CDS). The overall evaluationwasthattheproductbenefit/riskprofileremains positive.   |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0517  | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.8oftheSmPCtoincludethe ADR'bullous dermatitis'. C.I.4-Change(s) in the SPC, Labelling or PL due to | 20/03/2014   | 04/07/2014   | SmPC         | TheMAHhassubmittedacomprehensivereportwiththe purpose of reviewing the potential association of skin events with valsartan containing medications, including Exforge andExforge HCT and respective clones.It is consideredjustified toupdatethelistofADRs insection4.8 'undesirable effects'of the Exforge SmPC and Exforge HCT SmPCandtheirrespectiveclonesbasedonadditional informationfromasmallnumberofpost-marketingcases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     | reporting bullous rash occurring with valsartan. This amendmentdoesnotchangethebenefitriskbalancefor these products whichremainspositive.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0508/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. -changeinthe specificationlimits ofsome intermediatesusedinthemanufactureoftheactive substance, -additionofanewspecificationparameterswith theircorrespondingtestmethodstothespecification ofsome intermediatesused in themanufacture of the active substance and - change in test procedures for some intermediates used in themanufacture of the activesubstance. B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its | 20/02/2014 | n/a |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.1.c-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in testprocedure forAS or starting material/reagent/intermediate - Other changes to a testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in testprocedure forAS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.1.c-Change in the specification parameters   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |                                |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
|           | A.5.b - Administrative change - Change in the name and/oraddressofamanufacturer/importerofthe finished product, including quality control sites (excludingmanufacturerforbatchrelease)                                                                                                                                                                                                                                                                                                                                                                                                       | 20/01/2014 | n/a | IG/0400                        |
| IG/0390/G | Thiswasanapplicationforagroupofvariations. A.7-Administrativechange-Deletionof manufacturing sites A.7-Administrative change-Deletion of manufacturing sites B.I.a.1.f-Change in themanufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace A.4-Administrative change-Changein thename and/oraddressof amanufactureror anASMFholder orsupplieroftheAS,startingmaterial,reagentor intermediateusedinthemanufactureof theASor manufacturerofanovelexcipient | 12/12/2013 | n/a |                                |
|           | This was an applicationfor a group of variations. B.I.b.1.b-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof                                                                                                                                                                                                                                                                                                                                                                                                               | 22/11/2013 | n/a | IG/0376/G specification limits |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method                                                                                                                                                    |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0460 | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateofsection4.5of theSmPCtoincludefurther informationregardinganinteractionbetween valsartan and lithium. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/11/2013 | 04/07/2014 | SmPC | The MAH has reviewed the clinical databases of four large outcomes studies (Val-HeFT, Value, Valiant, and Navigator) for adverse eventreports of lithium toxicity.Further,the NovartisSafetyDatabase(ARGUS)was searched forall cases where both valsartan and lithium were reported as co-administered,andaliteraturesearchwasperformedfor published studies. The available data suggest a possible reversible interaction betweenvalsartan andlithium,although the exact mechanismhasnotbeenestablished.Thedataidentified arelimited andnoconfirmatoryevidencewasavailable from the clinical trials performed. TheSmPChasbeenupdatedtoinformprescribersofthe factthatreversibleincreasesinserumlithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, angiotensinIIreceptorantagonistsincludingvalsartan or thiazides.Sincerenal clearance of lithium isreduced by thiazides,theriskof lithiumtoxicitymaypresumablybe increasedfurtherwithvalsartan.Therefore,careful monitoringofserumlithiumconcentrationsis recommendedduringconcomitantuse. |
| IG/0355 | B.II1.1.a.2-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability tothe relevantPh.Eur.Monograph-Updated certificate                                                                                                                                                                                                                           | 30/09/2013 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|         | from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                                   |                                                                                                    |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------|----------------------------------------------------------------------------------------------------|
| IG/0349 | B.III.1.a.4-Submission of a new/updated or deletionofPh.Eur.CertificateofSuitability tothe relevantPh.Eur.Monograph-Deletion of certificates (in case multiplecertificatesexistper material)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 27/08/2013 | n/a        |                                   |                                                                                                    |
| WS/0359 | This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. Update ofSmPC sections 4.2,4.3,4.4 and 4.5 to reflectthatthe concomitantuseofAngiotensinII ReceptorBlockers(ARBs)orAngiotensin-Converting- Enzyme inhibitors (ACEi) with aliskiren is contraindicated in patients with renal impairment and in patients with diabetes mellitus. Further, section4.4oftheSmPChasbeenupdatedtoinform prescribers that caution is required, and monitoring ofbloodpressure,renalfunctionandelectrolytes is recommended, when co-administering agents acting on therenin angiotensin aldosterone system(RAAS) i.e.ACEi,ARBsoraliskirenasadirectrenininhibitor. The Package Leaflet has been updated accordingly. In addition,theMAH tookthe opportunity toupdate theSmPC,AnnexIIandthePackageLeafletinline withthelatestQRDtemplate,toimplementminor editorialchangesinthelabelling andPackageLeaflet and toaddthecontactdetailsof theCroatianlocal representativein thePackage Leaflet. | 27/06/2013 | 31/07/2013 | SmPC, Annex  II, Labelling and PL | Pleasereferto theScientificDiscussion\"ExforgeHCT- Dafiro HCT-Copalia HCT-EMEA-H-C-xxxx-WS-359-AR\". |

<div style=\"page-break-after: always\"></div>

|           | of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------|
| IG/0269/G | This was an application for a group of variations. B.1.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.III.1.a.2 - Submission of a new or updated Ph. Eur. Certificate ofSuitability to therelevantPh.Eur. Monograph - Updated certificate from an already                                                                                                                                                                         | 22/02/2013 | n/a | approved manufacturer |
| IG/0248   | C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17/12/2012 | n/a |                       |
| WS/0333/G | This was an application for a group of variations following a worksharing procedure according to Article20of CommissionRegulation(EC)No 1234/2008. Tochangethespecifications and testproceduresfor hydrochlorothiazide(theactive substance)andfor an intermediateusedinthemanufactureof theactive substancehydrochlorothiazide. B.I.b.1.b-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Tighteningof specification limits B.1.b.1.b-Change in the specification parameters | 13/12/2012 | n/a |                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of an AS, starting material/intermediate/reagent-Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significantspecificationparameter(e.g.deletion of anobsoleteparameter) B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.2.b-Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate,ifanalternativetest procedure is already authorised B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changes toa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.a - Change in test procedure for AS or   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.1.z-Changeinthespecificationparameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.2.a-Change in test procedure forAS or starting material/reagent/intermediate-Minor changesto anapprovedtestprocedure B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a-Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor   |            |            |             |                                                                                                                                                                                                                                                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0233   | B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificateof Suitabilityto therelevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 13/11/2012 | n/a        |             |                                                                                                                                                                                                                                                                   |
| WS/0252/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/09/2012 | 31/10/2012 | SmPC and PL | Thesafetyupdateof theSmPCandPackageLeafletwas basedonareviewof theMAH'ssafety andclinical trial data bases, published literature for both the amlodipine and valsartan components, a recommendation by the US FDA aswellastherecentrevisedandharmonisedamlodipine |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |            | However, as angioedema is a potentially life-threatening andfataladverseeffect,thereviewedliteraturehighlights thatACE-inhibitors orARBsshouldbeusedwith caution in patientswith anyhistory of this condition. ThesafetydataprovidedbytheMAH isregarded as sufficientinordertojustifytheproposedwarningon angioedema'insection4.4oftheSmPC.Itshouldalsobe notedthatawarningregarding'angioedema'isalready included in the SmPC for Diovan (valsartan monotherapy). Additional changes to the wording of warnings already includedinSmPCsection4.4（renalarterystenosis\", \"heart failure\" and \"aortic and mitral valve stenosis\") were alsomadeaspartofthisprocedureinordertoprovide further clarity to thehealthcareprofessional. Inaddition,theMAHtooktheopportunity toupdatethe amlodipinesectionsoftheSmPCinaccordancewiththe harmonised product informationfor Norvasc(amlodipine   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0250/G | This was an application for a group of variations following a worksharing procedure according to Article20ofCommissionRegulation(EC)No 1234/2008. WS-0250-Gwasagroupofvariations consistingof two Type II variations following a worksharing procedure according to Article 20 of Commission Regulation(EC)No1234/2008asfollows: Variation1:Updateofsection4.5oftheSmPCto add information about thepotential druginteraction betweenamlodipine andsimvastatin,andupdate of the existing amlodipine information in section 4.5 in | 19/07/2012 | 30/08/2012 | SmPC andPL | Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in somepatients,resultinginincreased blood pressure lowering effects. Concomitantuseofamlodipinewithstrongormoderate CYP3A4inhibitors(proteaseinhibitors，azoleantifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem)may give rise to significant increase in amlodipineexposure.Theclinical translation of these pharmacokineticvariationsmaybemorepronouncedinthe elderly.Clinical monitoring anddoseadjustmentmay thus be required. ThereisnodataavailableregardingtheeffectofCYP3A4                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | linewiththereviseddruginteractionssectionfor Norvasc(amlodipine monotherapy).ThePackage Leaflethasbeen updated accordingly; Variation2:Updateofsection4.5oftheSmPCto add information about the potential drug interaction betweenvalsartanandinhibitorsoftheuptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir). The Package Leaflet has been updated accordingly. C.I.4 -Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical,clinical orpharmacovigilancedata C.I.4-Variationsrelatedto significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |     | inducersonamlodipine.TheconcomitantuseofCYP3A4 inducers (e.g. rifampicin, Hypericum perforatum) may give a lowerplasma concentration of amlodipine.Amlodipine shouldbeusedwithcautiontogetherwithCYP3A4 inducers. Co-administrationofmultipledosesof10mgamlodipine with80mgsimvastatinresultedina77%increase in exposuretosimvastatincomparedtosimvastatinalone.It is recommended to limit the dose of simvastatin to 20 mg daily in patients on amlodipine. In animals,lethalventricularfibrillation and cardiovascular collapseareobservedinassociationwithhyperkalaemia afteradministrationofverapamilandintravenous dantrolene.Due toriskof hyperkalaemia,it is recommended thattheco-administrationofcalcium channelblockerssuchasamlodipinebeavoidedinpatients susceptible tomalignanthyperthermia and in the management of malignanthyperthermia. In clinical interaction studies, amlodipine did not affect the pharmacokineticsofatorvastatin,digoxin,warfarinor ciclosporin. Theresultsof an invitro study withhuman liver tissue indicatethatvalsartanis asubstrateof thehepaticuptake transporterOATPiB1andofthehepaticeffluxtransporter MRP2.Co-administrationofinhibitorsoftheuptake transporter(rifampicin,ciclosporin)oreffluxtransporter   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0209/G | This was an applicationfor a group ofvariations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/08/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | system as described in the DDPS - Change in the contactdetailsoftheQPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof thepharmacovigilancesystem                                                                                                                                                                                                                                              |            |            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|
| WS/0282   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. toaddanewspecificationparameterforimpuritiesin the active substance. B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its                                                                                                   | 19/07/2012 | 19/07/2012 |
| IG/0200/G | This was an application for a group of variations. B.I.a.1.f-Change in the manufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Changein themanufacturer of ASor of a starting material/reagent/intermediate for AS - Changestoquality controltesting arrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place | 13/07/2012 | n/a        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.1.f-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batchcontrol/testing takesplace B.I.a.1.f-Change in themanufacturer of ASor of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.III.1.a.2 -Submission of a new or updated Ph.Eur. Certificate ofSuitability to the relevant Ph.Eur. Monograph-Updatedcertificatefrom analready approved manufacturer A.5.b-Administrative change-Change in the name and/oraddressofamanufacturerofthefinished product, including quality control sites (excluding   |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0253/G | Thiswas anapplicationfor agroupofvariations followingaworksharingprocedureaccordingto Article20ofCommissionRegulation(EC)No 1234/2008. WS-0253-G is a group of two variations (one type II &onetypeIB)following aworksharingprocedure as follows:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 24/05/2012 | 28/06/2012 | SmPC | The safety of amlodipine in human pregnancy has not been established.Reproductivestudiesinratsandmicehave showndelayeddateofdelivery，prolongeddurationof labouranddecreasedpupsurvival atdosages approximately 50 times greater than the maximum recommended dosageforhumansbasedonmg/kg.Use in pregnancy is only recommended when there is no safer alternativeandwhenthediseaseitselfcarriesgreaterrisk |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| -Type IIvariation:Update of section 4.6of the SmPCwithwording onfertility in line with theSmPC forDiovan(valsartanmonotherapy)and5.3ofthe SmPCtoimplementthechangestotheSmPCfor Diovan that was approved as part of a recent Article 30 (referral) procedure; - Type IB variation: Update of sections 4.6 and 5.3 of theSmPCtoimplementthechangestotheSmPCfor Norvasc (amlodipine monotherapy) that was approved as part of a recent Article 30 (referral) procedure. C.I.1.b - Change in the SPC, Labelling or PL following areferralprocedure-Theproduct isnotcoveredby the defined scope of the referral but the change implementstheoutcomeofthereferralandnonew additional data aresubmitted by theMAH C.I.z - Changes (Safety/Efficacy) of Human and VeterinaryMedicinalProducts-Othervariation   | for the mother andfoetus. Reversiblebiochemical changesintheheadofspermatozoa havebeenreportedinsomepatientstreatedbycalcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. There was no effectonthefertilityofratstreatedwith amlodipine(males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat studyinwhichmaleratsweretreatedwithamlodipine besilatefor30days atadosecomparablewiththehuman dose based on mg/kg, decreased plasma follicle-stimulating hormone andtestosteronewerefoundaswell asdecreases inspermdensity andinthenumberofmaturespermatids and Sertoli cells. Rats andmice treatedwith amlodipineinthedietfor two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, andforratstwice*themaximumrecommendedclinical doseof10mgonamg/m2basis)wasclosetothe maximum tolerateddoseformicebutnotforrats. Mutagenicity studies revealed no drug related effects at eitherthegeneorchromosomelevels. * Based on patient weight of 50 kg Valsartanhadnoadverseeffectsonthereproductive performanceofmaleorfemaleratsatoraldosesupto200 mg/kg/day.Thisdoseis6timesthemaximum recommendedhumandoseonamg/m2basis(calculations assume anoraldoseof 320mg/day and a60-kgpatient). Non-clinicaldatareveal nospecial hazardforhumans   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                     |            |            |             | repeated dose toxicity, genotoxicity, carcinogenic potential. In rats, maternally toxic doses (600 mg/kg/day) during the lastdaysofgestationandlactationledtolowersurvival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6).These doses in rats(600mg/kg/day)are approximately 18 times the maximum recommended humandose ona mg/m2basis(calculations assume an oral dose of 320 mg/day and a 60-kg patient). In non-clinical safety studies,high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of redbloodcellparameters(erythrocytes,haemoglobin, haematocrit)andevidenceofchangesinrenal haemodynamics(slightly raisedplasma urea,and renal tubularhyperplasia andbasophilia inmales).These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18timesthemaximumrecommendedhumandoseona mg/m2basis(calculations assume anoral doseof320 mg/day and a 60-kgpatient). Inmarmosetsatsimilardoses,thechangesweresimilar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine. Hypertrophyof therenal juxtaglomerularcellswasalso seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which producesprolongedhypotension,particularlyin marmosets. For therapeutic doses of valsartan in humans, thehypertrophyof therenaljuxtaglomerularcellsdoesnot   |
|---------|-----------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0172 | This was an application for a variation following a | 24/05/2012 | 28/06/2012 | SmPC and PL | TheMAH hasundertakenthefollowingin-depthreview of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Updateof thesafetyandpharmacokinetic informationintheSmPCrelatedtothe hydrochlorothiazide component of the fixed-dose combination.As a consequence, sections 4.2, 4.4, 4.5,4.6,4.8 and5.2of theSmPChavebeen updated and the Package Leaflet has been updated accordingly.In addition, the MAH has taken the opportunity to implement editorial changes in the SmPCandPackageLeaflet and toupdatethecontact detailsofthelocalrepresentativesinthePackage Leaflet.   | the clinicalsafety andclinicalpharmacologyinformation availabletodateontheHCTZcomponentofthefixed-dose combination: ReviewofEsidrex(containingHCTZ,firstauthorisedin Switzerlandin1958,nationally authorised in39countries) PSURs1-6(1 Oct 1989-31 Dec 2009); Cases/eventsfromtheMAHsGlobalSafetyDatabase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (NGSD):NGSDwasreviewedcumulatively(cut-offdate13 Apr 2010) for all cases (spontaneous reports including literaturereportsaswell asserious adverseeventsfrom clinical trials)toidentify anyunlistedevent clustersfor Esidrex.Nonewunlistedeventclusterwasidentifiedinthe summarytabulationfromthesafetydatabasesearch; Literature review: Major drug reference books, including Martindale(HCTZ)and Meyler's side effects(thiazide diuretics), were reviewed for unlisted adverse reactions, andbridgingliteraturesearchesuptothecut-offdateof13 Apr2010wereperformed asperPSURsearchcriteria (publication date from the PSUR 6 cut-off date: 31 Dec 2009). As a consequence,sections 4.2,4.4,4.5,4.6,4.8 and 5.2 of theSmPChavebeenupdatedand thePackageLeaflet has been updated accordingly. Section4.4oftheSmPChasbeenupdatedtoincludeanew warningonthepotential riskof'acuteangle-closure glaucoma'associatedwiththeuseofhydrochlorothiazide. Hydrochlorothiazide,asulphonamide,hasbeenassociated withanidiosyncraticreactionresultinginacutetransient myopiaandacuteangle-closureglaucoma.Symptoms includeacuteonsetofdecreasedvisual acuityorocular pain and typically occur within hours to a week of |
| C.I.4-Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | treatmentinitiation.Untreatedacute-angleclosure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     | glaucoma canlead topermanentvisionloss. The primary treatment is to discontinue hydrochlorothiazide asrapidly aspossible.Promptmedical orsurgical treatment mayneedtobeconsideredif theintraocularpressure remains uncontrolled. Risk factors for developing acute angle closure glaucoma may include a history of sulphonamide or penicillin allergy. Further,thefollowingnewADRshavebeenadded to section 4.8 of the SmPC: asthenia, pyrexia, erythema multiforme,aplastic anemia,renaldisorder,muscle spasm and acute angle-closure glaucoma.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0190/G | This was an applicationfor a group of variations. B.Ill.1.a.1-Submissionofa neworupdatedPh.Eur. CertificateofSuitabilitytotherelevantPh.Eur. Monograph-Newcertificatefrom analready approved manufacturer B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to therelevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer B.1.b.1.d-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of an obsolete parameter) | 15/06/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IG/0148/G | Thiswas anapplicationfor agroupofvariations. C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the                                                                                                                                                                                                                                                                                                                                                                                                                                                | 22/02/2012 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | major contractual arrangements with other persons ororganisationsinvolvedinthefulfilmentof pharmacovigilanceobligationsanddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS -Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------|
| IB/0009/G | This was an application for a group of variations. B.II.b.1.e-Replacementoradditionofa manufacturing site for the FP - Site where any manufacturing operation(s) takeplace,exceptbatch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.a-Change tobatch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place A.5.b-Administrative change -Change in the name and/oraddressofamanufacturerofthefinished product,including quality control sites(excluding manufacturer for batch release) A.5.b-Administrative change -Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturerforbatchrelease) B.II.b.3.a - Change in the manufacturing process of thefinished product-Minor change in the manufacturing process of an immediate release solid | 11/11/2011 | n/a | oraldosageformororalsolutions |

<div style=\"page-break-after: always\"></div>

| B.II.b.3.a - Change in the manufacturing process of the finished product-Minor change in the manufacturing process of an immediate release solid oraldosageformororalsolutions B.II.b.3.a - Change in the manufacturing process of thefinishedproduct-Minor change in the manufacturing process of an immediate release solid oraldosageformororalsolutions B.II.b.3.a-Change in the manufacturing process of the finished product-Minor change in the manufacturingprocessofanimmediatereleasesolid oraldosageformororalsolutions B.I1.b.4.a-Changeinthebatchsize(includingbatch size ranges) of the finished product -Up to 10-fold compared to the currently approved batch size B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product-Other variation   |            |     |           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| This was an applicationfor a group of variations. C.I.9.e-Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the majorcontractualarrangementswithotherpersons or organisations involved in the fulfilment of pharmacovigilanceobligationsanddescribedinthe DD C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                  | 11/07/2011 | n/a | IG/0088/G |

<div style=\"page-break-after: always\"></div>

|           | This was an applicationfor a group ofvariations. B.I.a.2.a-Changes in the manufacturingprocess of the AS - Minor change in the manufacturing process of theAS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its                                                                                                                                       | 16/06/2011   | n/a        |                   | IG/0073/G corresponding test method   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|---------------------------------------|
| IG/0058   | B.Ill.1.a.2-SubmissionofaneworupdatedPh.Eur. CertificateofSuitabilitytotherelevantPh.Eur. Monograph-Updatedcertificatefrom analready approved manufacturer                                                                                                                                                                                                                                                                                                                                 | 13/04/2011   | n/a        |                   |                                       |
| WS/0097   | This was an application for a variation following a worksharingprocedureaccordingtoArticle20of CommissionRegulation(EC)No1234/2008. Toextend theshelf-lifeofthefinishedproductfrom 18monthsto2years.The MAH has also taken the opportunity to update the Annex II.B with the latest wording as per the October and November 2010 CHMPproceduralannouncement. B.II.f.1.b.1-Stability of FP-Extension of the shelf lifeof thefinishedproduct-Aspackagedforsale (supported by real time data) | 17/02/2011   | 17/03/2011 | SmPC and Annex II |                                       |
| WS/0088/G | This was an application for a group of variations following a worksharing procedure according to                                                                                                                                                                                                                                                                                                                                                                                           | 17/02/2011   | 17/02/2011 |                   |                                       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Article 20 of Commission Regulation (EC) No 1234/2008. to change the specification limit for an impurity in the active substance ; toaddnewtestproceduresfortheactivesubstance toaddnewspecificationsin theactivesubstance todeletea testprocedurefortheactive substance. B.I.b.1.c -Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding testmethod B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Tightening of specification limits B.I.b.2.e-Change in testprocedure forAS or startingmaterial/reagent/intermediate-Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e -Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.b-Change in test procedure forAS or startingmaterial/reagent/intermediate-Deletionof a testprocedurefortheASor a starting   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | procedure is already authorised B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate - Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------|
| IG/0032/G | Thiswas an applicationfor a group of variations. ToupdatetheDetailedDescriptionofthe PharmacovigilanceSystem(DDPS)toversion9.0,to include: -a change inthedeputyof theQualifiedPersonfor Pharmacovigilance (QPPV); - a change in the major contractual arrangements. - administrative changes not impacting the operation of the pharmacovigilance system. AnnexII.Bhasalsobeenupdatedwith thelatest wording as per October 2010 CHMPprocedural announcement. C.I.9.c-Changes to an existingpharmacovigilance system as described in the DDPS - Change of the back-upprocedure of theQPPV C.I.9.e-Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the majorcontractualarrangementswithotherpersons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.h - Changes to an existing pharmacovigilance | 21/12/2010 | n/a | system as described in the DDPS -Other change(s) |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | totheDDPSthatdoesnotimpactontheoperationof the pharmacovigilance system                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------|
| IB/0007/G | This was an application for a group of variations. B.I.a.1.z-Change in the manufacturer ofASor of a starting material/reagent/intermediate for AS - Other variation A.4-Administrative change -Change in the name and/oraddressof amanufacturerorsupplierof the AS, starting material, reagent or intermediate used inthemanufactureof theAS A.7-Administrativechange-Deletionof manufacturing sites B.I.a.1.f - Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.a-Change in the manufacturer of ASor of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer A.4-Administrativechange-Changeinthename and/oraddressofamanufacturerorsupplierofthe AS,startingmaterial,reagentorintermediateused | 27/10/2010 | n/a        | inthemanufactureoftheAS |
| I1/0005   | Minor change in the manufacturing process of the active substancevalsartan.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/09/2010 | 27/09/2010 |                         |

<div style=\"page-break-after: always\"></div>

|           | B.I.a.2.z - Changes in the manufacturing process of theAS-Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |                                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------|
| IA/0006/G | This was an application for a group of variations. B.II.b.1.a-Replacementoradditionofa manufacturing site for the Fp - Secondary packaging site B.II.b.1.b-Replacement or addition of a manufacturing site for the Fp - Primary packaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/09/2010 | n/a | site                                         |
| IB/0003/G | Thiswas anapplicationfor a group of variations. B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoatestprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.b.2.e-Change in test procedure forAS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate A.7-Administrativechange-Deletionof manufacturing sites B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to the relevantPh.Eur. Monograph - Updated certificate from an already approved manufacturer B.Ill.1.a.1-SubmissionofaneworupdatedPh.Eur. | 22/06/2010 | n/a | CertificateofSuitabilitytotherelevantPh.Eur. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Monograph - New certificate from an already approved manufacturer B.III.1.a.2-Submission of a new or updated Ph.Eur. Certificate of Suitability to therelevantPh.Eur. Monograph-Updatedcertificatefrom an already approved manufacturer B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding test method B.I.b.1.d-Change in the specificationparameters and/or limits of an AS, starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of an obsoleteparameter) B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changes to an approved test procedure B.I.b.1.c-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionofanew specification parameter to the specification with its corresponding testmethod B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0002/G | Thiswas an applicationfor a group of variations. B.II.d.1.a-Change in the specificationparameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 22/06/2010 | n/a |

<div style=\"page-break-after: always\"></div>

|         | and/or limits of the finished product - Tightening of specification limits B.II.d.1.c - Change in the specification parameters and/orlimitsof thefinishedproduct-Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.d-Change in the specification parameters and/orlimitsofthefinishedproduct-Deletion of a non-significant specification parameter (e.g. deletion of anobsoleteparameter   |            |            |          |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|
| IA/0004 | B.I.a.3.a -Change inbatch size (including batch size ranges)ofASorintermediate-Up to10-fold increasecomparedtothecurrentlyapprovedbatch size                                                                                                                                                                                                                                                                                                        | 18/06/2010 | n/a        |          |
| I1/0001 | Changes to QPPV UpdateofSummaryofProductCharacteristics UpdateofDDPS(Pharmacovigilance)                                                                                                                                                                                                                                                                                                                                                             | 18/02/2010 | 23/03/2010 | Annex II |